In a new study, @canersaygin.bsky.social and colleagues show that TP53-mutant ALL is a high-risk, chemo-resistant subtype with poor survival, highlighting the need for tailored strategies.
ow.ly/lvwo50WHJIr
Blood Cancer Journal - Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults
